A Phase II Study With Decitabine, Low Dose Cytarabine and G-CSF in High-Risk Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia or Acute Myeloid Leukemia in Patients With Significant Co-Morbidities.

Trial Profile

A Phase II Study With Decitabine, Low Dose Cytarabine and G-CSF in High-Risk Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia or Acute Myeloid Leukemia in Patients With Significant Co-Morbidities.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2013

At a glance

  • Drugs Decitabine (Primary) ; Cytarabine; Granulocyte colony-stimulating factors
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 May 2011 Planned End Date changed from 1 Aug 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 17 May 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov as reported by ClinicalTrials.gov.
    • 16 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top